VRDN - NASDAQ

Viridian Therapeutics, Inc.

VRDN·NASDAQ

$16.92

+6.6%

HealthcareBiotechnology

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.52B

EPS-3.3200

P/E Ratio-5.10

Earnings Date08/05/2026

vrdn

Other Current Assets

Last Annual Value

19.58M

3-Year CAGR

44%

5-Year CAGR

10-Year CAGR

51%

Adjust for Inflation

Viridian Therapeutics, Inc. Competitors Analysis of Other Current Assets

VRDN · NASDAQ

Company	Other Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Viridian Therapeutics, Inc. NASDAQ:VRDN	19.58M	29.5%	N/A	60.7%
uniQure N.V. NASDAQ:QURE	20.51M	97.7%	50.3%	32.0%
Cogent Biosciences, Inc. NASDAQ:COGT	9.59M	23.7%	N/A	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	11.01M	50.7%	87.1%	N/A
Edgewise Therapeutics, Inc. NASDAQ:EWTX	13.28M	15.6%	N/A	N/A
Structure Therapeutics Inc. NASDAQ:GPCR	124.11M	170.3%	N/A	N/A
Arcus Biosciences, Inc. NYSE:RCUS	26.00M	-4.7%	12.1%	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	10.86M	11.0%	N/A	22.8%
Celldex Therapeutics, Inc. NASDAQ:CLDX	14.08M	37.1%	N/A	N/A
ImmunityBio, Inc. NASDAQ:IBRX	3.89M	-9.3%	5.6%	19.4%

Viridian Therapeutics, Inc. Fair Value Envelope

VRDN · NASDAQ

Our analysis suggests that VRDN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.9196, this represents a potential HIDDEN relative to our calculated worth for Viridian Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $16.9196

Related Guides

Blog Categories

Continue your VRDN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.